These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 20570903)

  • 1. Synthetic lethality through combined Notch-epidermal growth factor receptor pathway inhibition in basal-like breast cancer.
    Dong Y; Li A; Wang J; Weber JD; Michel LS
    Cancer Res; 2010 Jul; 70(13):5465-74. PubMed ID: 20570903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
    Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
    Li B; Chang CM; Yuan M; McKenna WG; Shu HK
    Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis.
    Zhou Y; Li S; Hu YP; Wang J; Hauser J; Conway AN; Vinci MA; Humphrey L; Zborowska E; Willson JK; Brattain MG
    Cancer Res; 2006 Jan; 66(1):404-11. PubMed ID: 16397255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.
    Block M; Gründker C; Fister S; Kubin J; Wilkens L; Mueller MD; Hemmerlein B; Emons G; Günthert AR
    Int J Oncol; 2012 Nov; 41(5):1845-54. PubMed ID: 22922893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors.
    Buck E; Eyzaguirre A; Rosenfeld-Franklin M; Thomson S; Mulvihill M; Barr S; Brown E; O'Connor M; Yao Y; Pachter J; Miglarese M; Epstein D; Iwata KK; Haley JD; Gibson NW; Ji QS
    Cancer Res; 2008 Oct; 68(20):8322-32. PubMed ID: 18922904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity.
    Lai CJ; Bao R; Tao X; Wang J; Atoyan R; Qu H; Wang DG; Yin L; Samson M; Forrester J; Zifcak B; Xu GX; DellaRocca S; Zhai HX; Cai X; Munger WE; Keegan M; Pepicelli CV; Qian C
    Cancer Res; 2010 May; 70(9):3647-56. PubMed ID: 20388807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downregulation of Notch pathway by a gamma-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model.
    Efferson CL; Winkelmann CT; Ware C; Sullivan T; Giampaoli S; Tammam J; Patel S; Mesiti G; Reilly JF; Gibson RE; Buser C; Yeatman T; Coppola D; Winter C; Clark EA; Draetta GF; Strack PR; Majumder PK
    Cancer Res; 2010 Mar; 70(6):2476-84. PubMed ID: 20197467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.
    Dominguez-Escrig JL; Kelly JD; Neal DE; King SM; Davies BR
    Clin Cancer Res; 2004 Jul; 10(14):4874-84. PubMed ID: 15269164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.
    Dai Q; Ling YH; Lia M; Zou YY; Kroog G; Iwata KK; Perez-Soler R
    Clin Cancer Res; 2005 Feb; 11(4):1572-8. PubMed ID: 15746062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.
    Qin B; Ariyama H; Baba E; Tanaka R; Kusaba H; Harada M; Nakano S
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):577-84. PubMed ID: 16532343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy.
    Stratford AL; Habibi G; Astanehe A; Jiang H; Hu K; Park E; Shadeo A; Buys TP; Lam W; Pugh T; Marra M; Nielsen TO; Klinge U; Mertens PR; Aparicio S; Dunn SE
    Breast Cancer Res; 2007; 9(5):R61. PubMed ID: 17875215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells.
    Amin DN; Bielenberg DR; Lifshits E; Heymach JV; Klagsbrun M
    Microvasc Res; 2008 May; 76(1):15-22. PubMed ID: 18440031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast.
    Chan KC; Knox WF; Gee JM; Morris J; Nicholson RI; Potten CS; Bundred NJ
    Cancer Res; 2002 Jan; 62(1):122-8. PubMed ID: 11782368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
    Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
    Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level.
    Campiglio M; Locatelli A; Olgiati C; Normanno N; Somenzi G; Viganò L; Fumagalli M; Ménard S; Gianni L
    J Cell Physiol; 2004 Feb; 198(2):259-68. PubMed ID: 14603528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.
    Janmaat ML; Kruyt FA; Rodriguez JA; Giaccone G
    Clin Cancer Res; 2003 Jun; 9(6):2316-26. PubMed ID: 12796401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.
    Guix M; Granja Nde M; Meszoely I; Adkins TB; Wieman BM; Frierson KE; Sanchez V; Sanders ME; Grau AM; Mayer IA; Pestano G; Shyr Y; Muthuswamy S; Calvo B; Krontiras H; Krop IE; Kelley MC; Arteaga CL
    J Clin Oncol; 2008 Feb; 26(6):897-906. PubMed ID: 18180460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors.
    Choi YJ; Rho JK; Jeon BS; Choi SJ; Park SC; Lee SS; Kim HR; Kim CH; Lee JC
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):381-8. PubMed ID: 19921194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.